Chikungunya market seen reaching $1 billion by 2030

The global chikungunya market is forecast to grow from $0.65 billion in 2025 to $1 billion by 2030, according to a new report from The Business Research Company. The outlook reflects rising mosquito-borne disease rates, more vaccine investment and wider use of diagnostics and vector control.

Why it matters: - The chikungunya market is expanding as mosquito-borne illnesses become a bigger public health challenge worldwide. - The report points to stronger demand for vaccines, diagnostics and supportive care as governments and health systems look for better ways to manage outbreaks. - The market forecast signals more commercial activity around prevention and treatment tools tied to emerging infectious diseases.

What happened: - The Business Research Company published its Chikungunya Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The market is projected to rise from $0.65 billion in 2025 to $0.71 billion in 2026. - The report forecasts the market will reach $1 billion by 2030. - The report is available through a full market report. - A free sample of the report is also available.

The details: - The report pegs 2025-2026 growth at a 9.4% compound annual growth rate. - The forecast period through 2030 implies 9.1% annual growth. - Historical growth is tied to rising mosquito-borne viral infections, climate-driven expansion of endemic areas, limited approved vaccines, reliance on symptomatic treatments and stronger public health surveillance. - Future growth is expected to come from vaccine development investment, preventive healthcare, vector control efforts, rapid diagnostic tools and global funding for emerging infectious diseases. - Expected trends include chikungunya vaccine candidates, wider antiviral use, earlier diagnosis, more supportive care options and better mosquito-borne disease monitoring systems. - Chikungunya is a viral disease spread mainly by infected Aedes aegypti and Aedes albopictus mosquitoes. - Common symptoms include fever, severe joint pain, headaches, rash and muscle aches. - The report says those symptoms can materially affect quality of life and create demand for management and treatment options. - The report says the growing prevalence of mosquito-borne diseases such as chikungunya, dengue and Zika is a major growth driver. - Climate change, rapid urbanization, deforestation, stagnant water, weak vector control, more international travel and insecticide resistance are increasing infection risk. - Chikungunya treatments focus on symptom relief, including fever reduction, pain management, inflammation control, hydration and supportive care. - In December 2024, the UK Health Security Agency reported 473 dengue cases among travelers returning to England, Wales and Northern Ireland from January to June 2024, up 201% from 157 cases in the same period in 2023. - North America held the largest share of the global chikungunya market in 2025. - Asia-Pacific is expected to post the fastest growth over the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated technology and trend analysis.

Between the lines: - The market outlook is being shaped less by a single drug breakthrough and more by broader prevention and surveillance needs. - The regional split suggests established demand in North America and faster expansion in areas where mosquito-borne disease pressure is rising. - The inclusion of diagnostics, monitoring and vector control in the forecast shows the market extends beyond treatments alone.

What's next: - Vaccine pipelines, rapid tests and antiviral therapies are likely to remain the main commercial areas to watch. - Public health agencies and private developers may increase investment as climate and travel patterns keep expanding mosquito-borne disease exposure. - The market will likely be shaped by how quickly better prevention tools move from development into wider use.

The bottom line: - Chikungunya is moving from a niche infectious disease category toward a larger prevention and treatment market, with growth through 2030 driven by rising disease pressure and better tools to detect and manage outbreaks.